A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 4, 1997, Pages 347-352

  Planting, André ^a   Kho, Siang ^b   Van Der Burg, Maria ^a   Goey, Hoo ^a   Schellens, Jan ^a   Van Den Bent, Martin ^a   Van Der Gaast, Ate ^a   De Boer Dennert, Maureen ^a   Stoter, Gerrit ^a   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cisplatin; Dose intensity; Non small cell lung cancer; Oral etoposide

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; METOCLOPRAMIDE; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CEREBRAL BLINDNESS; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HEARING LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 8544262893     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050668     Document Type: Article

References (42)

1. Anderson G, Peel ET, Cheong CMB, Broderick NJ (1982) Etoposide - an effective single drug for treating bronchogenic carcinoma. Clin Oncol 8: 215
2. Bhuchar VK, Lanzotti VJ (1982) High-dose cisplatin for lung cancer. Cancer Treat Rep 66: 375
3. Britell JC, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S (1978) cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 62: 1207
4. Casper ES, Gralla RJ, Kelsen DP, Cvitkovic E, Golbey RB (1979) Phase 11 study of high-dose cis-dichlorodiammineplatinum(ll) in the treatment of non-small cell lung cancer. Cancer Treat Rep 63: 2107
5. Corder MP, Elliot TE, Bell SJ (1977) Dose limiting myelotoxicity in absence of significant nephrotoxicity with a weekly out-patient schedule of cis-platinum(II)diamminechloride. J Clin Hematol Oncol 7: 645
6. Crinò L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C, Meacci M, Corgna E, Darwish S, Scarcella L, Santuci A, Ballatori E, Tonato M (1995) Chemotherapy of advanced non-small cell lung cancer. A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 6: 347
7. De Jager R, Longeval E. Klastersky J (1980) High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 64: 1341
8. Dodwell DJ, Gurney H, Thatcher N (1990) Dose intensity in cancer therapy. Br J Cancer 61: 789
9. Donnadieu N, Paesmans M, Sculier JP (1991) Chemotherapy of non-small cell lung cancer according to disease extent: a metaanalysis of the literature. Lung Cancer 7: 243
10. Eagan RT, Ingle JN, Creagan ET, Frytak S, Kvols LK, Rubin S, McMahon RT (1978) VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 62: 843
11. Falkson G, Dyk JJ van, Eden EB van, Van der Merwe AM, Van der Berg JA, Falkson HC (1975) A clinical trial of the oral form of 4′-dimethyl-epipodophyllotoxin-β-D-ethylidene glueoside (NSC 141540, VP 16-213). Cancer 35: 1141
12. Forastiere AA, Takasugi BJ, Baker SR, Wolf GT, Kudla-Hatch V (1987) High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 19: 155
13. Gandara DR, Wold HG, Perez EA, Deisseroth AB, Doroshow J, Myers F, McWhirter K, Hannigan J, DeGregorio MW (1989) Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and 8 high-dose regimen. J Natl Cancer Inst 81: 790
14. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor SM, Braun TJ, Natale RB, Balcerzak SP (1993) Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the South West Oncology Group. J Clin Oncol 11: 873
15. Gelder T van, Geurs P, Kho GS, Dippel DWJ, Vecht ChJ, Splinter TAW (1993) Cortical blindness and seizures following cisplatin treatment: both of epileptic origin? Eur J Cancer 10: 1497
16. Gralla RG, Casper ES, Kelsen DP, Braun DW, Dukeman ME, Martini N, Young CW, Golbey RB (1981) Cisplatin plus vindesine combination chemotherapy for advanced carcinoma of the lung. A randomized trial investigating two dosage schedules. Ann Intern Med 95: 414
17. Greco FA (1993) Chronic etoposide administration: overview of clinical experience. Cancer Treat Rev 19 [Suppl]: 35
18. Higano CS, Crowley J, Livingston RB, Goodwin JW, Barlogie B, Stuckey WJ (1991) A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. Cancer 67: 2439
19. Hilkens PHE, Planting AST, Burg MEL van der, Moll JWB, Putten WLJ van, Vecht CJ, Bent MJ van den (1994) Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. Eur J Neurol 1: 45
20. Hryniuk WM (1988) The importance of dose intensity in the outcome of chemotherapy. In: De Vita VT. Hellman S. Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 121-141
21. Kim S, Howell SB, McClay E, Kirmani S, Goel R, Plaxe S, Braly P, Bonetti A (1993) Dose intensification of cisplatin chemotherapy through biweekly administration. Ann Oncol 4: 221
22. Klastersky J (1986) Therapy with cisplatin and etoposide for non-small-cell lung cancer. Semin Oncol 13 [Suppl 3]: 104
23. Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, Rocmans P, Bonduelle Y, Mairesse M, Michiels T, Thiriaux J, Mommen P, Dalesio O, the EORTC Lung Cancer Working Party (1986) A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 4: 1780
24. Lee JS, Scott C, Komaki R, Fossella FV, Dundas GS, McDonald S, Byhardt RW, Curran WJ (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 14: 1055
25. Mabel JA, Little AD (1979) Therapeutic synergism in murine tumors for combinations of cis-diamminedichloroplatinum with VP 16-213 or BCNU. Proc Am Assoc Cancer Res 20: 230
26. Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225S
27. National Cancer Institute (1989) Common toxicity criteria. Cancer Therapy Evaluation Program. Division of Cancer Treatment. National Cancer Institute, Bethesda, Maryland
28. Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Kennedy BJ, Ellison RR, Silver RT, Weiss RB, Cuttner J, Falkson G, Kung F, Bergevin PR, Holland JF (1980) Clinical trial of VP 16-213 (NSC 141540) iv twice weekly in advanced neoplastic disease. Cancer 45: 232
29. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899
30. O'Dwyer PJ, Langer CJ, Walczak J, Levy MH, Padavic-Shaller K, Hudes GR, Litwin S, Comis RL (1991) Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer. Eur J Cancer 27: 1589
31. Ozols RF, Ostecha Y, Myers CE, Young RC (1985) High-dose cisplatin in Hypertonic saline in refractory ovarian cancer. J Clin Oncol 3: 1246
32. Pannetiere FJ, Vance RB, Stuckey WJ, Coltman CA, Costanzi JJ, Chen TT (1983) Evaluation of single-agent cisplatin in the management of non-small cell carcinoma of the lung: a Southwest Oncology Group study. Cancer Treat Rep 67: 399
33. Planting AST, Burg MEL van der, Boer-Dennert M de, Stoter G, Verweij J (1995) Phase 1 study of weekly high-dose cisplatin combined with long term oral etoposide in advanced solid tumors. Ann Oncol 6: 190
34. Randolph VL, Wittes RE (1978) Weekly administration of cis-diamminedichloroplatinum(II) without hydration or osmotic diuresis. Eur J Cancer 14: 753
35. Rossof AH, Bearden JD III, Coltman CA (1976) Phase II evaluation of cis-diamminedichloroplatinum(II) in lung cancer. Cancer Treat Rep 60: 1679
36. Ruckdeschel JC (1990) Is chemotherapy for metastatic non-small-cell lung cancer "worth it"? J Clin Oncol 8: 1293
37. Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP (1979) cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459
38. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP (1993) Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342: 19
39. Splinter T, Kok T, Kho S, Lameris H, Kate F ten, Dalesio O, Dolman B, Palmen F, Bouvy J, Simonis F, Harper P, Rankin E, Reijswoud I van, Hoogenhuijze J van (1986) A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. Semin Oneol 13 [Suppl 3]: 97
40. Vogl SE, Berenzweig M, Camacho F, Greenwald E, Kaplan BH (1982) Efficacy study of intensive cisplatin therapy in advanced non-small cell bronchogenic carcinoma. Cancer 50: 24
41. Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M. Greco FA (1992) Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 10: 292
42. WHO (1979) Handbook for reporting results of cancer treatment. Offset publication 48. WHO, Geneva